tinea%20capitis
TINEA CAPITIS
Tinea capitis  is a contagious dermatophytosis affecting the hair shaft and follicles of the scalp, eyebrows and eyelashes.
It is most common in the crowded areas as infection originates from contact with a pet or an infected person and asymptomatic carriage persists indefinitely.
It primarily affects children 3-7 years of age.
The causative agents are the genus Trichophyton and Microsporum.
Cardinal clinical feature is the combination of inflammation with hair breakage and loss.
Drug Information

Indication: Relief of external thrush symptoms.

Indication: Dermatophytoses, mycoses & various fungi, pityriasis versicolor, infection & superinfection (gm +ve). ...

Indication: Topical treatment of dermatophyte skin infections eg, tinea corporis, tinea cruris, tinea manus & tinea pe...

Indication: Cap: Vulvovag & oral candidosis; dermatomycosis, plantar tinea pedis & palmar tinea manus, pityriasis ...

Indication: Tinea pedis, cruris, corporis & versicolor; cutaneous candidiasis.

Indication: Acute or recurrent genital & vag candidiasis, candidal balanitis, dermatomycosis including tinea pedis, ti...

Axcel Ecozalon
econazole nitrate + triamcinolone acetonide

Indication: Eczema, inflammatory dermatoses w/ mycotic &/or bacterial infection caused by dermatophytes, yeast & m...

Indication: Cryptococcosis ie, cryptococcal meningitis & infections of other sites (eg, pulmonary, cutaneous). Mainten...

Indication: Fungal skin infections including candidiasis, tinea & pityriasis versicolor.

Indication: Management of superficial candidiasis & fungal skin infections eg, mucocutaneous candidiasis, dermatophyto...

1  /  8
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Audrey Abella, 06 Aug 2019
The guideline-recommended, single-tablet, fixed-dose regimen comprising bictegravir, emtricitabine, and tenofovir alafenamide (B/F/TAF) was noninferior to the dolutegravir and F/TAF (D/F/TAF) regimen in persons living with HIV (PLHIV), according to data presented at IAS 2019.